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Abstract We describe here a novel c.137+5G > A intronic
mutation in the SH2D1A gene of the signaling lymphocyte
activation molecule (SLAM)-associated protein (SAP) in as-
sociation with Epstein-Barr virus (EBV)-induced fatal infec-
tious mononucleosis (FIM) in an 8-year-old male patient and
his 3-year-old step brother. The mother and the maternal
grandmother of the boys are healthy and heterozygous for this
sequence variant. Genetic sequencing of blood-cell-derived
cDNA in the younger patient revealed a 22 bp deletion in the
SH2D1A cDNA. Immunoblot and flow cytometry analysis
performed in this younger patient showed the lack of SAP
protein expression in peripheral blood lymphocytes. These
data suggest that the novel c.137+5G > A mutation results
in loss of function of SAP protein and leads to typical X-
linked lymphoproliferative disease phenotype. We propose
that intron 1 and the c.137+5G may be the most frequent
intronic hot spot for SH2D1A splicing mutation.
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Introduction
X-linked lymphoproliferative disease (XLP) (OMIM #611432)
is a recessive primary immunodeficiency disorder (PID) char-
acterized by aberrant immunoregulation [1, 2]. The clinical
phenotype of XLP includes Epstein-Barr virus (EBV)-
induced fa ta l in fec t ious mononucleos is (FIM),
hypogammaglobulinemia, vasculitis, and lymphoma localized
typically to the ileocecal region of the gastrointestinal tract
[3–5]. Intriguingly, patients with XLP are not particularly sus-
ceptible to infection by viruses other than EBV. Immunological
studies of affected individuals have revealed that T lymphocytes
and NK cells fail to mediate effective virus-specific cytotoxicity
towards EBV-infected B cells resulting in overwhelming lym-
phoproliferation and macrophage activation [6, 7].
Hypogammaglobulinemia and lymphoma may develop before
patients encounter EBV. Transitional CD24+CD38+ B cells are
present in the blood of patients but these cells fails to develop
normally into CD27+ memory B cells [8–10]. In the majority of
patients, XLP is caused by inactivating mutations in the
SH2D1A gene encoding the signaling lymphocyte activation
molecule (SLAM)-associated protein (SAP) [11, 12].
Mutations in BIRC4, the gene encoding X-linked inhibitor of
apoptosis protein (XIAP) may also result in XLP [1, 13]. To
date, more than 100 different sequence variant in SH2D1A
including missense, nonsense, frameshift, deletion, insertion,
and slice site mutations have been identified in XLP patients
[1, 5, 11, 12]. The vast majority of mutations affect exonic
sequences; one mutation in intron 3, five mutations in intron 2,
and seven mutations in intron 1 have been reported (Fig. 1) [1,
10, 14–21].
We have identified a previously unknown c.137+5G > A
intronic sequence variant in a male patient who died of FIM
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(Patient 1). This mutation carried by his mother and maternal
grandmother was also detected in his step brother (Patient 2).
We have performed detailed genetic andmolecular analyses of
the novel mutation in Patient 2.We report here that the c.137+
5G > A intronic single nucleotide change resulted in a 22 bp
deletion in the SH2D1A cDNA sequence. We propose that
intron 1 and the c.137+5G position may be the most frequent
intronic hot spot for SH2D1A splicing mutation.
Materials and Methods
Patients
All studies reported here were approved by the Regional
Ethics Committee of the University of Debrecen. Informed
consent was obtained from the mother of the patients.
Patient P1 was born in 2000 to healthy Hungarian parents.
He received routine immunization with no complications. He
developed non-itching eczematous rush in early childhood
over the wrists, elbows, and ankles which persisted for years
and were treated with local agents. At age 6 he developed pain
and limitation of movement in several joints including the
knees, uncles, and wrists, as well as the proximal interphalan-
geal, distal interphalangeal and metacarpophalangeal joints.
Despite the lack of swelling and warmth he was put on
metothrexate and methylprednisolone after evaluation by a
rheumatologist. Side effects developed soon and methylpred-
nisolone treatment was stopped 2 months and metothrexate
after 6 months of therapy. Joint pain and weakness recurred
and histopathological examination of a soft tissue sample
including skin, fascia and muscle tissues taken from the right
thigh was performed which revealed vasculitis. At age 8 he
presented with exudative tonsillopharyngitis and prolonged,
high fever and was treated with amoxicillin, amoxicillin-
clavulanic acid, and cefzil with no clinical improvement.
Chest and sinus maxillaris X-ray showed no signs of sino-
pulmonary infection. After 2 weeks of recalcitrant fever, liver
enzymes started to elevate (GLT, 137 U/L; GOT, 101 U/L) and
he developed thrombocytopenia (platelet number, 30 G/L),
neutropenia (granulocyte number, 0.29 G/L) and anemia (he-
moglobin, 97.2 g/L). His general condition and cardiorespira-
tory status rapidly deteriorated, he developed multiple organ
failure and pancytopenia and bone marrow smears showed
hemophagocytosis suggesting FIM. EBV DNA copy number
in the plasma and the cerebrospinal fluid were 97,320/ml and
5830/ml, respectively; EBV gDNA in peripheral blood mono-
nuclear cells (PBMCs) and bone marrow cells were 16.1 μg/g
and 8.0 μg/g, respectively. He died 3 weeks after the onset of
febrile disease. Sequence analysis of the SH2D1A gene re-
vealed hemizygous c.137+5G > A intronic mutation for which
the mother and maternal grandmother were both heterozygous.
Patient 2 was born in 2011 from uneventful pregnancy and
the second marriage of the mother. He received immunization
with no complication over the first 3 years of life and has had
no remarkable clinical infection or other disease manifesta-
tion. Genetic analysis revealed that he was also hemizygous
for the c.137+5G > A intronic mutation. Thus, we performed
detailed molecular analysis to define if this intronic sequence
variant might be pathological. This patient underwent success-
ful hematopoietic stem cell transplantation by using matched-
unrelated donor cells.
Methods
Isolation of Genomic DNA (gDNA) and RNA EDTA blood
from patients, family members, and controls was obtained and
gDNA was isolated by using Gen ELUTE Blood Genomic
DNA mini kit (Sigma-Aldrich Ltd., Germany). Total RNA
was extracted from peripheral blood leukocytes using Trizol
reagent (Invitrogen Life Technology, Carlsbad, Calif.), and
RNAwas extracted following the manufacturer’s instructions.
The RNA was treated with RNase-free DNase (Thermo
Scientific, Rockford, IL, USA).
Preparation of cDNA The RNAwas reverse-transcribed with
Superscript III first-strand synthesis supermix (Invitrogen).
The prepared cDNAwas used for the subsequent polymerase
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Fig. 1 Fifteen splicing mutations
in the SH2D1A gene which have
been reported before and the one
published in this paper (*). Exons
are indicated with arabic numbers
in squares
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chain rection. Primers were designed to amplify exons 1–4 of
SH2D1A. The RT-PCR products were separated on 1 % aga-
rose gels, and directly sequenced.
Targeted Gene Sequencing Primer sequences used to amplify
exons 1–4 and the flanking intron regions of SH2D1A are
available on request. Mutational analysis was performed by
using the BigDye Terminator Cycle sequencing kit, and an
ABI 3130 analyzer (Applied Biosystems, Foster City, CA,
USA) [22]. The DNA mutation numbering was based on the
cDNA sequence (Ensembl: ENST00000371139) and the first
nucleotide is A in the translation initiation codon.
Real-time RT-PCR The RNA samples were reverse transcribed
(RT) with the Superscript III first-strand synthesis supermix
(Invitrogen) using random hexamer primers (Applied
Biosystems, Darmstadt, Germany). Quantitative real-time
PCR was performed with TaqMan assay (Hs00158978_m1:
Applied Biosystems). All PCR reactions were performed in
triplicates and specificity of PCR reaction was controlled by
template and no RT controls. The comparative Ct method was
used to quantify transcripts and to normalize for GAPDH.
Analysis of SAP Expression by Western Blotting (WB) PBMCs
were isolated from anti-coagulated peripheral blood samples
by Ficoll gradient centrifugation (Ficoll-Paque PLUS, GE
Healthcare, Little Chalfont, UK). PBMCs were seeded on 6-
well plates in 5 ml complete RPMI medium in 10% FBS with
Penicillin, 10,000 IU /mL, and Streptomycin,10,000 μg/mL
(PAA Laboratories GmbH, Pasching, Austria) at 1×106 den-
sity and incubated in the presence or absence of 2000 ng/ml
phytohaemagglutinin (Life Technologies, Carlsbad, CA,
USA) for 72 h. Cells were subsequently lysed in 200 μl 2X
Laemli buffer (62.5 mMTris–HCl, pH 6.8, 25% glycerol, 2%
SDS, 0.01 % Bromophenol Blue). Cell lysates were boiled for
5 min and clarified by centrifugation (16,000 g, 10 min at
room temperature) and aliquots corresponding to 5×105 cells
were run on 15 % SDS/PAGE gels followed by standard WB.
The presence of SAP was detected by a SAP-specific affinity
purified rabbit serum. The affinity purified rabbit anti-SAP
antibody specific to C-terminal 25 amino acids of SAP has
been described [11]. After addition of horseradish peroxidase-
conjugated donkey anti-rabbit Ig antibody (GE Healthcare,
Little Chalfont, United Kingdom, 1:5000 dilution), signals
were visualized by enhanced chemiluminescence (ECL,
Super Signal West Pico (Thermo scientific, Rockford, IL,
USA). Expression of actin was detected in parallel in each
sample by an actin-specific rabbit polyclonal antibody (Sigma
St. Louis, MO, USA, 1: 2000 dilution), as a loading control
[23].
Detection of Intracellular SAP Protein by Flow Cytometry One
hundred microliters of whole blood was incubated with
peridinin chlorophyll protein-conjugated mouse anti-CD3
(Becton Dickinson, San Jose, CA, USA), phycoerythrin-
conjugated mouse anti-CD8 (Sigma Aldrich) and
allophycocyanin-conjugated mouse anti-CD56 (Becton
Dickinson) for the surface staining for 20 min at room
temperature. The samples were fixed with Fix & Perm
“A” (Invitrogen, Camarillo, CA, USA) for 20 min at
room temperature in dark place [24]. After the washing step
Fix & Perm “B” (Invitrogen) was added to the samples for
permeabilization and the cells were incubated with purified rat
immunoglobulin G1 (IgG1) isotypic control (Beckton
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Fig. 2 The identification of the
mutation c.137+5G > Amutation
in intron 1 of SH2D1A. Direct
sequencing of exon 1 and part of
intron 1 demonstrated
hemizygous (Patients; dark
squares) and heterozygous
(mother and grandmother) single
base substitution of G > A at
position c.137+5. Pt, Patient
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Dickinson) or rat anti-SH2D1A unconjugated monoclonal
antibody (clone: KST-3) for 20 min at room temperature.
After washing, fluorescein isothiocyanate-conjugated goat
anti-rat IgG1 antibody diluted in Fix & Perm “B” was added
(Becton Dickinson) for 20 min at room temperature. After
washing, the cells were resuspended in 1 % paraformaldehyde
for the analysis by FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA) [18].
Results and Discussion
Analysis of SH2D1A gDNA and cDNA by Using PCR
Amplicons
Sequencing of the SH2D1A gene ofthe whole blood gDNA
revealed a novel mutation in intron 1 (c.137+5G > A) in both
patients and heterozygosity for this sequence variant in the
mother and maternal grandmother (Fig. 2). The father of
Patient 1 was wild-type. The father and grandfather of
Patient 2 were not available for genetic testing. Complete
cDNA amplification from blood leukocytes of Patient 2 dem-
onstrated a smaller band (352 bp) compared with that of the
mother and healthy control (374 bp) (Fig. 3a). Sequencing of
the cDNA demonstrated a 22 bp deletion (116_137del22bp)
in exon 1 of Patient 2 (Fig. 3b). This deletion could not be
detected in cDNA isolated from a normal control and from the
mother (Fig. 3c and d). The c.137+5G > A nucleotide change
may result in altered donor splice site, deletion of cDNA,
change of cDNA sequence, and as a consequence a truncated
SAP protein. Therefore, the amino acid sequence of the pro-
tein between positions 39 and 72 couldalso be altered. Real-
time-PCR analysis showed a complete lack of SH2D1A
cDNA expression in Patient 2 and decreased expression in
the mother (Fig. 4).
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Fig. 3 Identification of a 22 bp
deletion in exon 1 of cDNA from
Patient 2. a) cDNA amplicons of
Patient 2 and his mother. b–d)
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Fig. 4 Real-time PCR analysis showed a complete lack of SH2D1A
cDNA expression in white blood cells from Patient 2 and intermediate
expression in cells from the mother
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Analysis of SAP Expression by Western Blotting and Flow
Cytometry
Figure 5 shows the immunoblots of SAP expression in PHA-
induced blasts of Patient 2 and the heterozygous mother. In
concert with the clinical, immunological and genetic data,
SAP protein could not be detected with Western blot in the
patient’s cells in contrast to that seen in the father. Protein
expression in the blast cells from the mother was decreased as
indicated by the thickness of the bands (Fig. 5). Flow cytom-
etry analysis of CD3+CD8+CD56- (CD8), CD3-CD56+
(NK) and CD3+CD56+ (CD56+ T) cells revealed that SAP
expression in Patient 2 was virtually abrogated compared to
the expression of this protein in these cells from healthy
control (Fig. 6).
The novel intronic mutation we presented here is predicted
to result in splicing defect leading to reduction of SAP level in
T cells. Based on molecular analysis performed in this study
we suggest that the c. 137+5G > A mutation is disease-
causing and may result in severe XLP phenotype. Data pre-
sented in this report further support the concept the deep
intronic mutation in the SH2D1A gene may lead to XLP. In
a recent report an intronic c. 137+5G > C mutation was found
to associate with normal length and sequence of mRNA and
low level of SAP protein expression detected by Western blot
[10]. In contrast, we present here a 22 bp deletion in the
SH2D1A mRNA, and a complete lack of SAP protein
expression.
Intronic mutations are mostly localized in consensus donor
or acceptor splicing sites. easily detected by the analysis of
exon-intron boundaries of genomic DNA, however the muta-
tion deeper in the introns may not be considered pathologic
unless cDNA and protein analysis is applied. The identifica-
tion of c. 137+5G replacements may reflect the existence of
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Fig. 5 The c.137+5G > A intronic mutation abrogates expression of
SAP in phytohemagglutinin (PHA)-induced blasts from Patient 2.
Peripheral blood mononuclear cells isolated from Patient 2, his mother
and father were activated with 2000 ng/mL PHA. Expression of SAPwas
tested byWestern blot analysis of whole cell lysates corresponding to 5×
105 cells. Actin expression was detected as an internal loading control.
Jurkat cells were used as positive controls
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Fig. 6 Intracellular SAP expression in Patient 2 with XLP. Analysis of
intracellular SAP expression by flow cytometry in cells from healthy
controls (a) and Patient 2 (b). Lymphocytes were gated with anti-SAP
antibody (red) or IgG1 isotype control (green) and with FITC-conjugated
anti-rat IgG1 antibody. MFI median fluorescence intensity
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mutational hot spot in SH2D1A. In the SH2D1A gene, 15
splicing mutation were known, including three exonic and
12 intronic sequence variant have been reported including
the one published here. Eight out of the 12 intronic mutations
affect intron 1 of SH2D1A. Based on published data it is
possible that this intronic mutation may be a recurrent hot
spot in different ethnics groups. Thus screening for cDNA
137+5G mutation may provide early molecular diagnosis of
XLP.
In conclusion, our results indicate that analysis of cDNA
isolated from blood leukocytes or blast cells to detect intronic
mutation must be considered for XLP patients who have
undetectable SH2D1A mutation in exonic sequences.
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